Literature DB >> 32484998

Direct antimicrobial activity of cationic amphipathic peptide WLBU2 against Staphylococcus aureus biofilms is enhanced in physiologic buffered saline.

Jonathan B Mandell1,2, John A Koch1, Berthony Deslouches3, Kenneth L Urish1,4,5,6,7.   

Abstract

Periprosthetic joint infection of total knee arthroplasties represents a major challenge to the field of orthopedic surgery. These infections are commonly associated with antibiotic-tolerant Staphylococcus aureus biofilms. Engineered cationic amphipathic peptide WLBU2 has shown the ability to kill antibiotic-resistant pathogens and drug-tolerant bacterial biofilms. The novelty of using WLBU2 during the direct irrigation and debridement of periprosthetic joint infections led our group to investigate the optimal washout conditions for treatment of S. aureus biofilms. S. aureus mature biofilms were grown on metal implant material and treated with WLBU2 dissolved in differing irrigation solvents. Mature biofilms were treated both in vitro as well as in a periprosthetic joint infection murine model. WLBU2 activity against S. aureus biofilms was increased when dissolved in diphosphate-buffered saline (dPBS) with pH of 7.0 compared with normal saline with pH of 5.5. WLBU2 activity was decreased in acidic dPBS and increased in alkaline dPBS. WLBU2 activity could be decreased in hypertonic dPBS and increased in hypotonic dPBS. WLBU2 dissolved in less acidic dPBS displayed increased efficacy in treating periprosthetic joint infection (PJI) implants ex vivo. WLBU2 demonstrated the ability to eliminate PJI associated S. aureus biofilms on arthroplasty material. The efficacy of engineered cationic amphipathic peptide WLBU2 for intraoperative elimination of S. aureus biofilms can be further optimized when kept in a less acidic and more physiologic pH adjusted saline. Understanding optimal physical washout conditions are vital for the success of WLBU2 in treating S. aureus biofilms in PJI clinical trials going forward.
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals LLC.

Entities:  

Keywords:  antimicrobial peptide; biofilm, periprosthetic joint infection, Staphylococcus aureus

Mesh:

Substances:

Year:  2020        PMID: 32484998      PMCID: PMC7665995          DOI: 10.1002/jor.24765

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  27 in total

Review 1.  Amphipathic, alpha-helical antimicrobial peptides.

Authors:  A Tossi; L Sandri; A Giangaspero
Journal:  Biopolymers       Date:  2000       Impact factor: 2.505

Review 2.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

3.  De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity.

Authors:  Berthony Deslouches; Shruti M Phadke; Vanja Lazarevic; Michael Cascio; Kazi Islam; Ronald C Montelaro; Timothy A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Novel antimicrobial peptides derived from human immunodeficiency virus type 1 and other lentivirus transmembrane proteins.

Authors:  S B Tencza; J P Douglass; D J Creighton; R C Montelaro; T A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 5.  The therapeutic applications of antimicrobial peptides (AMPs): a patent review.

Authors:  Hee-Kyoung Kang; Cheolmin Kim; Chang Ho Seo; Yoonkyung Park
Journal:  J Microbiol       Date:  2016-12-30       Impact factor: 3.422

6.  Periprosthetic joint infection increases the risk of one-year mortality.

Authors:  Benjamin Zmistowski; Joseph A Karam; Joel B Durinka; David S Casper; Javad Parvizi
Journal:  J Bone Joint Surg Am       Date:  2013-12-18       Impact factor: 5.284

Review 7.  Biofilms: survival mechanisms of clinically relevant microorganisms.

Authors:  Rodney M Donlan; J William Costerton
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

8.  Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung.

Authors:  R Bals; X Wang; Z Wu; T Freeman; V Bafna; M Zasloff; J M Wilson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides.

Authors:  Jan G M Bolscher; Regina Adão; Kamran Nazmi; Petra A M van den Keybus; Wim van 't Hof; Arie V Nieuw Amerongen; Margarida Bastos; Enno C I Veerman
Journal:  Biochimie       Date:  2008-06-05       Impact factor: 4.079

Review 10.  Prosthetic joint infection.

Authors:  Aaron J Tande; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

View more
  4 in total

1.  Evolved resistance to a novel cationic peptide antibiotic requires high mutation supply.

Authors:  Alfonso Santos-Lopez; Melissa J Fritz; Jeffrey B Lombardo; Ansen H P Burr; Victoria A Heinrich; Christopher W Marshall; Vaughn S Cooper
Journal:  Evol Med Public Health       Date:  2022-05-30

Review 2.  Clinical Evidence of Current Irrigation Practices and the Use of Oral Antibiotics to Prevent and Treat Periprosthetic Joint Infection.

Authors:  Jason Zlotnicki; Alexandra Gabrielli; Kenneth L Urish; Kimberly M Brothers
Journal:  Orthop Clin North Am       Date:  2021-02-10       Impact factor: 2.472

3.  Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.

Authors:  David B Huang; Kimberly M Brothers; Jonathan B Mandell; Masashi Taguchi; Peter G Alexander; Dana M Parker; Dean Shinabarger; Chris Pillar; Ian Morrissey; Stephen Hawser; Parviz Ghahramani; Despina Dobbins; Nicholas Pachuda; Ronald Montelaro; Jonathan D Steckbeck; Kenneth L Urish
Journal:  PLoS One       Date:  2022-09-16       Impact factor: 3.752

Review 4.  The Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections.

Authors:  David Huang; Nicholas Pachuda; John Michael Sauer; Dessie Dobbins; Jonathan Steckbeck
Journal:  Antibiotics (Basel)       Date:  2021-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.